Physician profile
Asha Agarwal
NPI 1407844939
$801.13
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $285 · 2020: $324 · 2021: $192.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $445.02 | 2019-2021 | |
| Lilly USA, LLC | $134.62 | 2019-2021 | |
| Novo Nordisk INC | $58.37 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $54.99 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $33.94 | 2019-2021 | |
| Nestle Healthcare Nutrition INC. | $19.67 | 2021 | |
| Daiichi Sankyo INC. | $15.73 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.56 | 2021 | |
| Allergan, INC. | $12.83 | 2019 | |
| Pfizer INC. | $11.40 | 2020 |
1 company reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Asha Agarwal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.